Loading
NASDAQHealthcareBiotechnology
Latest quote
$12.622
+$0.602 · +5.01%
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Regular session
$12.622
+$0.602 · +5.01%
Regular session · ET · Market data may be delayed.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Day range
Current $12.622
52-week range
Current $12.622
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
63
Bullish
Risk
49
Elevated Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Day range
Current $12.622
52-week range
Current $12.622
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 75.13M USD | 28.83M USD | 38.03M USD | 485.42M USD | 375.2M USD |
| Cost of goods sold | 28.82M USD | — | — | 66.44M USD | 45.52M USD |
| Gross profit | 46.31M USD | 28.83M USD | 38.03M USD | 418.99M USD | 329.69M USD |
| Research and development | 186.83M USD | 167.26M USD | 175.66M USD | 107.88M USD | 62.06M USD |
| Selling, general, and administrative | 76.58M USD | 85.49M USD | 75.18M USD | 66.76M USD | 48.76M USD |
| Operating expenses | 263.41M USD | 343.6M USD | 275.23M USD | 202.48M USD | 125.27M USD |
| Interest income | 28.33M USD | 38.47M USD | 42.25M USD | 16.08M USD | 3.33M USD |
| Interest expense | — | — | — | 4.05M USD | 5.23M USD |
| Depreciation and amortization | 28.82M USD | 97M USD | 30.89M USD | 33.1M USD | 17.25M USD |
| Operating income | −217.1M USD | −314.77M USD | −237.21M USD | 216.51M USD | 204.41M USD |
| Net income | −146.41M USD | −162.86M USD | −146.4M USD | 158.52M USD | 153.46M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB23.23M0.22%10.41B USD0.44%$205.87+2.69%
iShares Genomics Immunology and Healthcare ETFIDNA7.88M2.58%307.68M USD0.47%$41.99+3.88%
State Street SPDR Portfolio Developed World ex-US ETFSPDW6.96M0.02%40.77B USD0.03%$49.845+0.37%
Fidelity Nasdaq Composite Index ETFONEQ1.11M0.01%10.94B USD0.21%$107.72+0.55%
Avantis U.S. Equity ETFAVUS831.53K0.01%14.77B USD0.15%$130.46+0.31%
Virtus Biotech Clinical Trials ETFBBC776.98K1.89%41.11M USD0.65%$44.2274+2.27%
Avantis U.S. Small Cap Equity ETFAVSC508.84K0.02%3.06B USD0.25%$69.97+0.01%
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN359.31K0.10%347.18M USD0.47%$45.58+0.53%iShares Biotechnology ETFIBBiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Developed World ex-US ETFSPDWFidelity Nasdaq Composite Index ETFONEQAvantis U.S. Equity ETFAVUSVirtus Biotech Clinical Trials ETFBBCAvantis U.S. Small Cap Equity ETFAVSCInvesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
